Helmholtz-Institut für Pharmazeutische Forschung Saarland (HIPS)

Strengthening International Collaboration in Science! 🌍🤝 We were honored to welcome Prof. Shengying Li to our institute, where he and our Scientific Director, Prof. Rolf Müller, officially signed a Memorandum of Understanding. This agreement lays the foundation for future collaboration between Shandong University, Helmholtz-Zentrum für Infektionsforschung and Helmholtz-Institut für Pharmazeutische Forschung Saarland (HIPS), fostering joint research and innovation. This partnership reflects our commitment to advancing scientific discovery through global cooperation. We look forward to exchanging knowledge, driving impactful research, and achieving new milestones together! 🚀

🚨 We're Hiring!  Are you passionate about #Biochemistry and ready to make an impact in #AntimicrobialResearch? We are looking for a Postdoctoral Researcher (f/m/d) to join our Antimicrobials through Chemoenzymatic Synthesis group! 🔬 Work on enzyme engineering, protein characterization, and biocatalytic applications 🤝 Collaborate with interdisciplinary teams in a state-of-the-art research environment 📍 Location: Saarbrücken, Germany Full job description & application details: https://lnkd.in/e8GB_5Sj

We keep an eye on #Pseudomonas! 👁️ A team of researchers from Universität des Saarlandes and the Helmholtz-Institut für Pharmazeutische Forschung Saarland (HIPS) has made a game-changing discovery in the fight against 𝘗𝘴𝘦𝘶𝘥𝘰𝘮𝘰𝘯𝘢𝘴 𝘢𝘦𝘳𝘶𝘨𝘪𝘯𝘰𝘴𝘢, a dangerous hospital germ responsible for severe eye infections and 1.5 million cases of blindness worldwide every year. 🔬 The Key Discovery: Instead of targeting the bacterium directly—risking antibiotic resistance—the team focused on LasB, a destructive enzyme that allows 𝘗. 𝘢𝘦𝘳𝘶𝘨𝘪𝘯𝘰𝘴𝘢 to damage the cornea. Alexander Kiefer and Christian Schütz, co-lead authors of the Advanced Science study, designed a peptide inhibitor that binds to the zinc complex in LasB, rendering it completely harmless. This prevents corneal damage while ensuring that essential human enzymes remain unaffected. Unlike conventional antibiotics, this approach has not triggered bacterial resistance. 💡 Why This Matters: ✔️ A novel therapeutic approach that doesn’t rely on conventional antibiotics ✔️ No observed resistance development—a major advantage over traditional treatments ✔️ Potential for combination therapy—enhancing the effectiveness of existing antibiotics This study, published in Advanced Science, is a promising step toward safer, more effective treatments for infectious keratitis and other 𝘗. 𝘢𝘦𝘳𝘶𝘨𝘪𝘯𝘰𝘴𝘢 infections. The next goal? Developing this approach into a viable drug—one that could protect millions from blindness. 🔍This way to read the full article on our website. ⬇ ⬇ ⬇ https://lnkd.in/emp7Yqij 🔬This way to the original publication. ⬇ ⬇ ⬇ https://lnkd.in/emSYyqdC #MedicalResearch #Biotechnology #InfectiousDiseases #DrugDiscovery #Innovation #PharmaceuticalResearch

Welcome to the 𝗣𝗵𝗮𝗿𝗺𝗮𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝗛𝘂𝗯 (𝗣𝗦𝗛) – where scientific excellence meets pharmaceutical innovation! 🔬 The 𝗣𝗦𝗛 is a collaboration platform between Saarland University and the Helmholtz Institute for Pharmaceutical Research Saarland. Built on more than 15 years of partnership, we are driving innovation in pharmaceutical research. Our goal is the rapid and efficient identification and development of pharmaceuticals against societally relevant diseases such as infections, cancer and age-related diseases. 💡 𝗢𝘂𝗿 𝗠𝗶𝘀𝘀𝗶𝗼𝗻: • Develop groundbreaking pharmaceutical solutions • Advance research on infections, cancer & age-related diseases • Connect academia and industry for stronger collaborations • Support scientific entrepreneurship and innovation 🚀 𝗢𝘂𝗿 𝗔𝗰𝗵𝗶𝗲𝘃𝗲𝗺𝗲𝗻𝘁𝘀: • 15+ years of successful partnership • 70+ members to date • 300+ scientific professionals • 20+ global industry collaborations • 10+ successful startup ventures Follow us on this channel for more insights, latest in pharmaceutical research, career opportunities, and scientific breakthroughs! Join the conversation! What are your thoughts on the future of pharmaceutical innovation? Let us know in the comments! 😊 Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) Universität des Saarlandes Saarland Informatics Campus Universitätsklinikum des Saarlandes #PharmaScienceHub #HelmholtzInstitutFürPharmazeutischeForschungSaarland #unisaarbrücken #PharmaceuticalResearch #Pharmaceuticals

🚨 More speakers announced! Don’t forget to register! 🚨 We’re excited to welcome three more fantastic speakers to the International Conference on Anti-Infectives 2025 (ICA 2025)! 🎤 Achim Hoerauf, Bonn University 🎤 Till Strowig, Helmholtz Centre for Infection Research 🎤 Claudia Zampaloni, F. Hoffmann-La Roche Ltd They join our international lineup of experts sharing the latest breakthroughs in anti-infective research, drug discovery, and development. 📅 Registration closes on 𝗠𝗮𝗿𝗰𝗵 𝟯𝟭, 𝟮𝟬𝟮𝟱!  If you haven’t signed up yet, now’s the time! 🔗 Register here: https://lnkd.in/eQ7asXwY Or scan the QR code. Looking forward to seeing you there!

Who knew stuffing engineered lactobacilli in a gel would make them better at secreting our engineered proteins? And there's more! It makes them more biocompatible and less acidic. A pleasant surprise for us and a great outcome for therapeutic engineered living materials - https://lnkd.in/db_YX69n Varun Tadimarri, Marc Blanch Asensio, Ketaki Deshpande, Sara Trujillo Muñoz, INM-Leibniz Institute for New Materials, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)

🚀 Registration is NOW OPEN! 🚀 We are thrilled to celebrate the 15th anniversary of the Helmholtz-Institut für Pharmazeutische Forschung Saarland (HIPS) by hosting the very first International Conference on Anti-Infectives 2025 (ICA 2025)! 🎉 📅 When: 20-22 May 2025 📍 Where: Saarland University campus, Saarbrücken, Germany Join us and connect with leading international experts in the field of anti-infective research. This is your chance to explore the latest innovations in discovery and development of anti-infectives, from cutting-edge methodologies to breakthrough technologies. Register now and learn more:  https://lnkd.in/eQ7asXwY We can’t wait to welcome you to this exciting event!

First spoiler: For all people interested in Anti-infective research, we have a very cool 3-day conference coming up in May following the footsteps of our HIPS symposium. Registrations are very modest and we have slots poster and talks covering topics on microbial natural products, microbiome research and drug research. Official announcement and registration options for the ICA2025 will be out soon.

We are thrilled to share the latest breakthrough from our institute in cooperation with TWINCORE GmbH, published in the European Journal of Medicinal Chemistry. The study, "Unlocking the Antiviral Arsenal: Structure-Guided Optimization of Small-Molecule Inhibitors against RSV and hCoV-229E", marks a significant step forward in the fight against viral infections. Key Highlights: 🦠 The research focuses on optimizing small-molecule inhibitors targeting Respiratory Syncytial Virus (RSV) and human coronavirus 229E (hCoV-229E). 🦠 A structure-guided approach led to the discovery of novel compounds demonstrating sub-micromolar potency, improved selectivity, and enhanced metabolic stability. 🦠 These advances provide a promising foundation for developing effective antiviral therapies, addressing the global need for cost-effective alternatives to vaccines and monoclonal antibodies. The findings emphasize the potential of structure-based drug design in tackling severe viral diseases and underscore the importance of collaborative efforts in medicinal chemistry and virology. 🔬This way to the original publication. ⬇ ⬇ ⬇ https://lnkd.in/e52GH2B7 Christina Karhan, Svenja Sake, Antonia Gunesch, Christina Grethe, Benedikt Hellwinkel, Natalie Köhler, Alexander Kiefer, Uladzislau Hapko, Andreas Kany, Thomas Pietschmann, Anna K. H. Hirsch

Don't miss the chance to meet Rolf in person! We’re thrilled to be part of this year’s AMR Conference in Basel, Switzerland. Looking forward to engaging discussions and innovative ideas!